Jacobs Levy Equity Management Inc. Trims Position in REGENXBIO Inc. (NASDAQ:RGNX)

Jacobs Levy Equity Management Inc. decreased its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 41.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 89,218 shares of the biotechnology company's stock after selling 63,219 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.18% of REGENXBIO worth $936,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. FMR LLC boosted its position in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 1,656 shares in the last quarter. nVerses Capital LLC grew its stake in REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 2,200 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company's stock worth $100,000 after purchasing an additional 3,720 shares in the last quarter. Diversified Trust Co acquired a new stake in REGENXBIO in the 2nd quarter valued at $121,000. Finally, Arizona State Retirement System raised its holdings in REGENXBIO by 20.6% during the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company's stock worth $137,000 after buying an additional 1,997 shares during the last quarter. Institutional investors own 88.08% of the company's stock.

Insider Activity at REGENXBIO

In related news, Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the transaction, the director now owns 11,286 shares in the company, valued at approximately $114,101.46. This represents a 46.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 13.13% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on RGNX shares. StockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, September 20th. Raymond James reissued an "outperform" rating and issued a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th. HC Wainwright cut their price target on shares of REGENXBIO from $40.00 to $36.00 and set a "buy" rating for the company in a research note on Thursday, November 21st. Morgan Stanley reiterated an "overweight" rating and issued a $22.00 price objective on shares of REGENXBIO in a report on Friday, November 15th. Finally, Chardan Capital reiterated a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $35.27.

REGENXBIO Trading Up 5.0 %

Shares of NASDAQ:RGNX traded up $0.48 during mid-day trading on Monday, reaching $10.06. The stock had a trading volume of 1,098,038 shares, compared to its average volume of 637,680. The business's 50 day moving average price is $9.81 and its 200 day moving average price is $11.57. The company has a market cap of $498.37 million, a P/E ratio of -2.08 and a beta of 1.24. REGENXBIO Inc. has a 1 year low of $8.44 and a 1 year high of $28.80.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.